Anthony B. Costales, MD, on Advanced Ovarian Cancer: Predicting the Benefits of Minimally Invasive Surgery
SGO 2021 Virtual Annual Meeting on Womens Cancer
Anthony B. Costales, MD, of the Baylor College of Medicine, discusses results from the MIID-SOC trial, which explored the question of whether laparoscopic surgery for removal of ovarian, fallopian tube, or primary peritoneal cancer following neoadjuvant chemotherapy is feasible, safe, and provides similar outcomes as open surgery.
The ASCO Post Staff
William H. Bradley, MD, of the Medical College of Wisconsin, discusses results from the SOLO-1 trial on maintenance olaparib after first-line platinum-based chemotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Almost half of the patients treated with olaparib in the study were disease-free at 5 years, vs 20% of those treated with placebo (ID# 10224).
The ASCO Post Staff
Eric Pujade-Lauraine, MD, PhD, of Hôpital Hôtel-Dieu, discusses results from the PAOLA-1ENGOT-ov25 trial on the use of homologous recombination–repair mutation gene panels and whether they can predict the efficacy of olaparib plus bevacizumab in first-line maintenance therapy for patients with ovarian cancer (ID# 10224).
The ASCO Post Staff
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results from the ENPAC trial, which showed the combination of enzalutamide, paclitaxel, and carboplatin yielded promising clinical outcomes in chemotherapy-naive advanced or recurrent endometrioid cancer (ID # 10244).
The ASCO Post Staff
Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses phase III results from the ENGOT-OV16/NOVA study on the long-term safety and efficacy of niraparib as maintenance therapy in patients with platinum-sensitive ovarian cancer with either a BRCA mutation or a tumor with high-grade serous histology. Women in the study have responded to their most recent chemotherapy containing a platinum agent (ID #: 11139).
The ASCO Post Staff
Emily Hinchcliff, MD, MPH, of The University of Texas MD Anderson Cancer Center, discusses phase II results of durvalumab (anti–PD-L1) and tremelimumab (anti–CTLA-4) administered in combination vs sequentially for the treatment of recurrent platinum-resistant non–clear cell ovarian cancer (ID #10240).
